Stephen Hermitage joins Sai Life Sciences as VP, CMC
PR98941
MANCHESTER, England and HYDERABAD, India, Nov. 22, 2022 /PRNewswire=KYODO JBN/ --
Sai Life Sciences, a leading global Contract Research, Development &
Manufacturing Organisation
(CRO-CDMO)(https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=st
ephen-h-joins-slsc), today announced the joining of Stephen Hermitage (Steve)
as Vice President, CMC. In this role Steve will join the global R&D leadership
team at Sai Life Sciences, where he will add further deep scientific, process
development and drug development experience to the R&D organisation.
Making the announcement, Sauri Gudlavalleti, Chief Operating Officer said,
"Over the past few years, our team has established a formidable reputation for
itself as a high-quality scientific unit that can solve complex chemistry
challenges. I am delighted to welcome Steve, a pharma industry veteran, onboard
at Sai Life Sciences. His addition to our global delivery team further
strengthens our ongoing efforts to build strong client partnerships and exceed
client expectations by raising the bar on innovation, speed, and efficiency.
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a
department head and member of the global chemical development leadership team.
Over 24 years at GSK Steve has successfully worked with many project leaders
and their teams to deliver the API and regulatory submissions that facilitate
preclinical and clinical activities across the whole development lifecycle -
from pragmatic accelerated early phase supply to complex Quality by Design
(QbD) control strategies supporting commercial file and launch. Throughout his
time with GSK Steve gained significant experience of working with CDMOs in
India
(https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=stephen-h-jo
ins-slsc), China and Europe having led the technical externalisation group
within Chemical Development.
Elaborating on Steve's role, Dean Edney, Global Head of Process R&D said,
"Steve will bring best practices in late phase chemical and API development
(https://www.sailife.com/services/manufacturing/late-phase-manufacturing/?utm_so
urce=pr&utm_medium=web&utm_campaign=stephen-h-joins-slsc) to programs across
Manchester and Hyderabad. His experience will also provide new perspectives on
project and program management, ensuring we continue to build towards
excellence in client partnership."
Steve holds a BA & MA from Oxford University, a PhD from Liverpool
University and conducted Postdoc studies at the University of Cambridge. He is
a Fellow of the Royal Society of Chemistry and Chartered Chemist (FRSC CChem).
Commenting on his appointment, Steve Hermitage said, "I am incredibly
excited to join Sai Life Sciences at a transformative time for the company.
Throughout all my interactions with colleagues in the company it is clear that
there is a collective ambition to build a world leading organisation that
delivers Projects for customers by blending strong science with efficient
manufacturing capability whilst maintaining high standards in Safety and
Quality."
About Sai Life Sciences
Sai Life Sciences is a full-service CRO-CDMO
(https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=stephen-h-jo
ins-slsc) that works with innovator pharma and biotech companies globally, to
accelerate the discovery, development and commercialisation of complex small
molecules. The company has over 2200 employees across its facilities in India,
UK and USA. Sai Life Sciences is privately held and backed by global investors,
TPG Capital and HBM Healthcare Investments. https://www.sailife.com/
Photo:
https://mma.prnewswire.com/media/1953372/Steve_Hermitage_Sai_Life_Sciences.jpg
Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg
Source: Sai Life Sciences
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。